share_log

While Shareholders of Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

While Shareholders of Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

杭州中泰低溫科技(SZSE:300435)的股東在過去三年虧損,但基礎收益實際上有增長
Simply Wall St ·  10/24 17:48

Hangzhou Zhongtai Cryogenic Technology Corporation (SZSE:300435) shareholders should be happy to see the share price up 24% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In fact, the share price is down 26% in the last three years, falling well short of the market return.

中泰股份(SZSE:300435)的股東應該很高興,看到股價在上個月上漲了24%。但這並不能掩蓋過去三年收益低於理想的事實。事實上,在過去三年中,股價下跌了26%,遠遠低於市場回報。

On a more encouraging note the company has added CN¥519m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.

更值得鼓舞的是,公司在過去7天內將51900萬人民幣增加到了其市值中,讓我們看看是什麼導致了股東在過去三年的虧損。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本傑明·格雷厄姆的話來說:「短期市場是一臺投票機,但長期市場是一臺稱重機」。檢查市場情緒如何隨時間推移變化的一種方式是查看公司股價和每股收益(EPS)之間的相互作用。

Although the share price is down over three years, Hangzhou Zhongtai Cryogenic Technology actually managed to grow EPS by 5.8% per year in that time. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.

儘管股價在過去三年中下跌,但中泰股份實際上在此期間成功實現了每年5.8%的每股收益增長。這是一個相當棘手的問題,表明可能有一些暫時支撐股價的因素。或者該公司過去受到過度炒作,因此其增長令人失望。

Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

由於EPS的變化似乎與股價的變化不相關,因此值得查看其他指標。

The modest 1.2% dividend yield is unlikely to be guiding the market view of the stock. Revenue is actually up 4.6% over the three years, so the share price drop doesn't seem to hinge on revenue, either. This analysis is just perfunctory, but it might be worth researching Hangzhou Zhongtai Cryogenic Technology more closely, as sometimes stocks fall unfairly. This could present an opportunity.

1.2%的股息率不太可能影響股票的市場觀點。實際上,營業收入在過去三年中增長了4.6%,因此股價下跌似乎並不取決於營業收入。這種分析只是敷衍了事,但值得更仔細地研究一下中泰股份,因爲有時股票會不公平地下跌。這可能帶來一些機會。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。

big
SZSE:300435 Earnings and Revenue Growth October 25th 2024
中小企業板300435在2024年10月25日的盈利和營業收入增長情況

If you are thinking of buying or selling Hangzhou Zhongtai Cryogenic Technology stock, you should check out this FREE detailed report on its balance sheet.

如果您考慮買入或賣出中泰股份的股票,您應該查看這份關於其資產負債表的免費詳細報告。

A Different Perspective

另一種看法

While the broader market gained around 8.8% in the last year, Hangzhou Zhongtai Cryogenic Technology shareholders lost 7.7% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.9% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Hangzhou Zhongtai Cryogenic Technology better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Hangzhou Zhongtai Cryogenic Technology , and understanding them should be part of your investment process.

儘管去年整體市場上漲了約8.8%,中泰股份的股東卻損失了7.7%(甚至包括分紅在內)。但是請記住,即使是最好的股票有時也會在一年的時間內表現不佳。遺憾的是,去年的表現可能表明存在未解決的挑戰,因爲它比過去半個十年的年化損失0.9%還要糟。我們意識到羅斯柴爾德男爵曾說過投資者應該「在街上有血時買入」,但我們警告投資者首先要確定他們正在購買的是一個高質量的業務。長期跟蹤股價表現總是很有趣。但要更好地理解中泰股份,我們需要考慮許多其他因素。例如,始終存在的投資風險。我們已經發現了1個關於中泰股份的警告標誌,了解它們應該成爲您投資過程的一部分。

But note: Hangzhou Zhongtai Cryogenic Technology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

請注意:中泰股份可能不是最好的買入股票。因此,請查看這份免費的有過盈利增長(以及未來增長預測)的有趣公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文中引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論